UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy

UniQure shares soared after the company said it can seek U.S. approval for its Huntington’s disease gene therapy before running a new study. The reversal signals a more permissive stance from the Trump administration on drug reviews and materially improves the program’s timeline and regulatory odds. The move is likely to be stock-specific rather than sector-wide, but it is clearly positive for UniQure’s valuation.

Analysis

UniQure shares soared after the company said it can seek U.S. approval for its Huntington’s disease gene therapy before running a new study. The reversal signals a more permissive stance from the Trump administration on drug reviews and materially improves the program’s timeline and regulatory odds. The move is likely to be stock-specific rather than sector-wide, but it is clearly positive for UniQure’s valuation.